Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February
Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras. He takes the place of